ArticleJournal of clinical medicine2022
Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials.Frontiers in immunology · 2025Pooled it
- Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Predictive biomarkers for immunotherapy response in endometrial cancer: current insights and future directions.Exploration of targeted anti-tumor therapy · 2026Review
- Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).Journal of gynecologic oncology · 2026Article
- Article
- Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system.Scientific reports · 2025Article
- Predictive factors of chemotherapy‑induced nausea and vomiting in elderly patients with gynecological cancer undergoing paclitaxel and carboplatin therapy: A retrospective study.Oncology letters · 2025Article
- Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation.ACS omega · 2025Article
- Multi-sequence MRI-based clinical-radiomics models for the preoperative prediction of microsatellite instability-high status in endometrial cancer.Precision radiation oncology · 2025Article
- PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature.Journal of clinical medicine · 2025Review
- microRNA profile of endometrial cancer from Indian patients-identification of potential biomarkers for prognosis.Biochemistry and biophysics reports · 2024Article
- Fertility preservation in patients with gynecologic cancer.World journal of clinical cases · 2024Article
- Analysis of the potential biological value of pyruvate dehydrogenase E1 subunit β in human cancer.World journal of gastrointestinal oncology · 2024Article
- Upregulation of TTK expression is associated with poor prognosis and immune infiltration in endometrial cancer patients.Cancer cell international · 2024Article
- Review
- Analysis of microsatellite instability (MSI) in pediatric gonadal and extra-gonadal germ cell tumors.Intractable & rare diseases research · 2023Article
- ERRα Up-Regulates Invadopodia Formation by Targeting HMGCS1 to Promote Endometrial Cancer Invasion and Metastasis.International journal of molecular sciences · 2023Article
- A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients.International journal of molecular sciences · 2023Article
- New Insights into Immunotherapy for Gynecological Cancer.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since endometrial cancers (ECs) are frequently TMB-H and MSI-H/dMMR tumors, this element has provided the rationale for testing immune checkpoint inhibitors (ICIs), which have recently emerged as a potential game-changer. However, several questions remain to be addressed, including the identification of patients who may benefit from the addition of ICIs as well as those who do not need immunotherapy. In the current paper, we provide an overview of the clinical development of immunotherapy in advanced or recurrent EC, discussing the role of MMR and the "elective affinities" between ICIs and this predictive biomarker in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.